Format

Send to

Choose Destination
Br J Pharmacol. 2017 Nov;174(22):3898-3913. doi: 10.1111/bph.13818. Epub 2017 Jun 10.

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?

Author information

1
Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
2
Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
3
Hypertension in Africa Research Team (HART), North-West University, Potchefstroom campus, South Africa.
4
Department of Pharmacy, University of Naples Federico II, Naples, Italy.

Abstract

Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore, the theoretical potential to manipulate the inflammatory response to prevent cardiovascular events. However, extrapolation to humans requires care and we still lack definitive evidence to show that interfering in immune-inflammatory processes may safely lessen clinical atherosclerosis. In this review, we discuss key therapeutic targets in the treatment of vascular inflammation, placing basic research in a wider clinical perspective, as well as identifying outstanding questions.

LINKED ARTICLES:

This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.

PMID:
28409825
PMCID:
PMC5660005
DOI:
10.1111/bph.13818
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center